

ASX Announcement

Tuesday, 19 December 2023

Third US Patent granted for Tissue Repair's Glucoprime®

Tissue Repair is pleased to announce its third US Patent application has been Allowed by the US Patent and Trademark Office (USPTO). The patent is entitled **BIOLOGICAL POLYSACCHARIDE COMPOUND** (US Patent No. 2023/0085802 A1) with the claims allowed in the application covering the Glucoprime® compound and molecule itself for any application whatsoever.

Glucoprime® and its variants is the underlying technology platform behind Tissue Repair's lead drug candidate TR987® for the treatment of Venous Leg Ulcers (VLUs) and its TR Pro+™ cosmeceutical product.

The technology has broad applications in any environment in animals or humans where there is a wound, when applied topically and/or within the body.

This patent now affords the protection for a variety of further applications to commercialise the company's core technology platform.

Importantly, the patent affords further robust protection for the commercialisation of its TR Pro+™ cosmeceutical product. TR Pro+™ is a next generation post procedure topical recently launched in a NSW pilot program and achieving robust monthly sales in some 90 clinics.

The Company has received significant and consistent feedback during the pilot from patients and clinicians alike on its superior in-use efficacy over incumbent products and the Company is now in exploratory discussions with parties on potential additional overseas distribution agreements for selected territories.

Tissue Repair's co-founder Tony Charara said:

"The patent protection across the three allowed patents now in force is robust. We have delivered on our prospectus objectives of securing solid IP protection at a critical point as we explore the next stage of commercialisation for TR Pro+™ and the planned Phase 3 Clinical Trial commencement for our lead drug candidate TR987®.

The latest third patent allowance follows the earlier allowance of Tissue Repair's USA second patent (US Patent No. 11,572,420 B1), with claims for use of the Company's Active Pharmaceutical Ingredient (API) Glucoprime® for topically applied methods of treating any skin condition and its first patent allowance in April 2022, with claims on the method of manufacturing Glucoprime® (US Patent No. 11,384,160 on 12 July 2022).

There are no known alternative processes from which to produce the Company's proprietary biological polysaccharide molecule.



Tissue Repair Ltd

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566



The table below provides an overview of the patent protection secured by the Company since listing.

Tissue Repair Limited - Table of Patent Protection

US Patent 1 Glucoprime GRANTED Methods of Manufacture Pub No US 11,384,160 B1 Date of Patent: Jul. 12, 2022	TOPICAL TREATMENTS USING A BETAGLUCAN COMPOUND The claims granted cover methods of MANUFACTURE of the Glucoprime® API, there are no other known methods to produce the API to the specifications required by the FDA which link directly to potency and efficacy and in turn clinical impact.
US Patent 2 US Divisional Patent Glucoprime GRANTED Method of Treatment Pub. No.: US 11,572,420 B1 Date of Patent: Feb. 7, 2023	METHODS OF USE AND METHODS OF MANUFACTURE THEREOF The claims allowed are relatively broad in terms of the type of skin treatment that may be treated. The only limitation in terms of treatment is that Glucoprime API is applied topically to the skin of a wound site. The broadest claim is not restricted in terms of the type of wound and what else the vehicle comprises apart from Glucoprime API.
US Patent 3 US Divisional Patent Glucoprime ALLOWED Composition Pub. No.: US 2023/0085802 A1 Publication Date: Mar. 23, 2023	BIOLOGICAL POLYSACCHARIDE COMPOUND The claims allowed in this application cover the compound itself for any application.
PCT Patent Application Glucoprime PENDING Pub. No.: WO 2023/004456 A1 Publication Date: Feb. 2, 2023	BIOLOGICAL POLYSACCHARIDE COMPOUND The claims in this application cover the method of manufacture, topical methods of treatment and the composition itself. All of the claims were found to be novel and inventive by the international examining authority.

Tissue Repair Limited ("TR") is the only advanced biotechnology company globally seeking to enter a Phase 3 drug program in VLUs in 2024.

If the trials for its lead drug candidate TR987® are successful, the Company will be the first drug approved for VLUs in over 25 years.

About Tissue Repair

Tissue Repair Limited (ASX TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company is a genuine Phase 3 clinical stage and is planning on shortly commencing its Phase 3 program in chronic wounds for its lead drug candidate TR987®. The Company has a secondary focus on commercialising TR Pro+™ a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer-term strategy is to commercialize its propriety Glucoprime® API to treat a variety of wounds and skin conditions.

For further information in relation to this release please contact Darryl Reed at darryl.reed@trtherapeutics.com 0419 557 663.

This announcement has been approved for release by TRP's Board.



Tissue Repair Ltd

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566